Research Paper|Volume 15, Issue 2|pp 567—582

Association of SMC4 with prognosis and immune infiltration of sarcoma

Guangyao Jiang¹, Junjie Chen², Yan Li¹, Jian Zhou³, Wanchun Wang³, Gen Wu⁴, Yupeng Zhang⁵

¹Department of Orthopedics, People's Hospital of Pingchang County, Pingchang, Sichuan 636400, China
²Department of Orthopedics, Longhui People’s Hospital, Shaoyang, Hunan 422200, China
³Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
⁴Department of Orthopedics, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, Guangdong 510900, China
⁵Department of Spine Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China

Received: August 13, 2022Accepted: January 23, 2023Published: January 30, 2023

https://doi.org/10.18632/aging.204503

Copyright: © 2023 Jiang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: This study was performed to explore the prognostic relevance of structural maintenance of chromosomes 4 (SMC4) in pan-cancer and explore the association between SMC4 and immune infiltration of sarcoma.

Results: Elevated expression of SMC4 was detected in cancer tissues compared to normal tissue, which was confirmed in synovial sarcoma tissues with immunohistochemistry (IHC). Additionally, higher expression of SMC4 was connected to worse outcomes of sarcoma, gastric cancer, breast cancer, liver cancer or ovarian cancer. Moreover, SMC4 was positively connected to immune cell infiltrates in sarcoma. In addition, infiltrating immune cell markers including monocyte, TAM, M1 and M2 presented different SMC4-associated immune infiltration patterns.

Conclusion: The results from our study showed that SMC4 was positively related to the prognosis and immunological status of sarcoma. SMC4 could be a potential biomarker for prognosis and immune cell infiltrates in sarcoma.

Methods: Several databases including ONCOMINE, GEPIA, and Kaplan-Meier Plotter were adopted to explore the expression pattern of SMC4 in sarcoma, which was confirmed by IHC. The GEPIA and TIMER datasets were adopted to investigate the associations between SMC4 and prognosis in various cancers, especially in sarcoma.